Funding Opportunity RFA-DA-20-010 from the NIH Guide for Grants and Contracts. There are two main purposes of the Rat Opioid Genome Project. The first is to tease out genetic, genomic, and molecular (epi)genetic variants that underlie phenotypes associated with distinct stages along the opioid use disorder (OUD) trajectory to identify potential targets for future interventions at early stages along the trajectory. The second is to identify genetic, genomic, and molecular (epi)genetic variants underlying comorbid conditions and/or phenotypes that can be used to develop therapeutics to save lives of people who are at the end stages of the OUD trajectory.

Funding Opportunity PAR-19-375 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed

Funding Opportunity RFA-CA-19-064 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations. The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. Specifically, the focus for observational studies (with pilot testing) is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment; and the focus for interventional research is on addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation and dissemination in low-income rural areas, so proposals should seek to develop, adapt, and/or implement, and test interventions.

Funding Opportunity RFA-OD-19-027 from the NIH Guide for Grants and Contracts. The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIPs trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.

Notice NOT-EB-19-020 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-075 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-20-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R61/12/R33 applications to develop interventions for physician compliance with recommended prevention guidelines for the elderly from the Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force (USPTF). Specifically, applicants will develop electronic health record (EHR)-based interventions to improve the quality of care and health outcomes, and reduce health disparities. This FOA will support an R261 pilot phase, which will allow researchers to use data analytics tools, including machine learning approaches, to establish the feasibility of identifying groups of patients not receiving recommended preventive care, and then create scalable, tailored interventions for these groups to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase for implementation of pragmatic trials. All applicants are required to address health disparities.

Notice NOT-OD-19-141 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-143 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-056 from the NIH Guide for Grants and Contracts. The purpose of the proposed Funding Opportunity Announcement (FOA) is to continue support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: 1) Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center, Clinical Trial Sites, Network Laboratories, and a Statistical Center. The AMC team must have at least four scientific disease-oriented Working Groups to study Kaposi Sarcoma, Lymphoma, Human papilloma virus-associated cancers, and non-AIDS-Defining cancers. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.

Funding Opportunity RFA-AI-19-063 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release (SER) drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA focuses on the following scientific priority DDS: low-volume, self-injectable depots, erosible/biodegradable implants including in situ forming implants, intrauterine delivery systems and transdermal delivery systems. Applications will require an industry partner. Applications incorporating drugs that are already under development or approved for HIV prevention and/or treatment by their intellectual property/patent/license holder must involve these persons/entities in a meaningful and significant manner in the application through letters of support and/or other evidence of a substantial commitment.

Funding Opportunity PAR-19-372 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and health disparity populations.

Notice NOT-DK-19-025 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-025 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-026 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-369 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not responsive to this FOA and will not be accepted.

Funding Opportunity PAR-19-365 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the latter years of their award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Funding Opportunity RFA-HL-20-006 from the NIH Guide for Grants and Contracts. The purpose of this program is to provide continued support to Transition Scholars who have successfully matriculated through the NIH Stimulating Access to Research in Residency (StARR) R38 program as resident investigators, and who demonstrate potential and continued interest in pursuing careers as clinician-investigators. Awards will provide 12-24 months of mentored research and career development support to those individuals who completed R38 research training, have secured a clinical fellowship or early-career faculty appointment (as instructor or assistant professor for less than 40 months at the time of submission or resubmission), and propose a strong research and career development plan towards continued, successful research careers.

Funding Opportunity PAR-19-368 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

Funding Opportunity RFA-HL-20-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.